(Q43801228)

26 November 2017

title

A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump (English)

1 reference

26 November 2017

1 reference

Raskin P

1

1 reference

26 November 2017

Holcombe JH

2

1 reference

26 November 2017

Tamborlane WV

3

1 reference

26 November 2017

Malone JI

4

1 reference

26 November 2017

Strowig S

5

1 reference

26 November 2017

Ahern JA

6

1 reference

26 November 2017

Lavent F

7

1 reference

26 November 2017

publication date

1 November 2001

1 reference

Journal of Diabetes and its Complications

26 November 2017

published in

1 reference

26 November 2017

volume

15

1 reference

26 November 2017

issue

6

1 reference

26 November 2017

page(s)

295-300

1 reference

Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Impact on clinical status and quality of life of switching from regular insulin to insulin lispro among patients using insulin pumps.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Strategies Toward Improved Control During Insulin Lispro Therapy in IDDM: Importance of basal insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Catheter obstruction with continuous subcutaneous insulin infusion. Effect of insulin concentration

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

The human insulin analogue insulin lispro

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Clinical use of the insulin infusion pump in 100 patients with type I diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Insulin-pump therapy: effect of phosphate-buffered human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900168-4

7 January 2021

10.1016/S1056-8727(01)00168-4

Identifiers

DOI

1 reference

26 November 2017

1 reference